Comparison of the oral delivery of three marketed Low Molecular Weight Heparins encapsulated in Nanoparticles | Archives | / | Publications

Menu Content/Inhalt

Home|Careers|Contact us

News

20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

Comparison of the oral delivery of three marketed Low Molecular Weight Heparins encapsulated in Nanoparticles

AAPS Baltimore, Nov 7-11, 2004

N. Ubrich, P. Maincent, F. El Ghazouani, E. Emond, C. Vigneron, E. Vuaridel, A. Carrio, S. Bernard, J.M. Dumont, B. Ducrey
poster_in_PDF